Cargando…

Characterization of patients that can continue conservative treatment for adenomyosis

BACKGROUND: Historically, hysterectomy has been the radical treatment for adenomyosis. Although, some patients may not want to have their uterus removed, patients often have to no choice but to request hysterectomy during conservative treatment. The factors necessitating these hysterectomies remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyagawa, Chiho, Murakami, Kosuke, Tobiume, Takako, Nonogaki, Takafumi, Matsumura, Noriomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714452/
https://www.ncbi.nlm.nih.gov/pubmed/34961515
http://dx.doi.org/10.1186/s12905-021-01577-x
_version_ 1784623916392644608
author Miyagawa, Chiho
Murakami, Kosuke
Tobiume, Takako
Nonogaki, Takafumi
Matsumura, Noriomi
author_facet Miyagawa, Chiho
Murakami, Kosuke
Tobiume, Takako
Nonogaki, Takafumi
Matsumura, Noriomi
author_sort Miyagawa, Chiho
collection PubMed
description BACKGROUND: Historically, hysterectomy has been the radical treatment for adenomyosis. Although, some patients may not want to have their uterus removed, patients often have to no choice but to request hysterectomy during conservative treatment. The factors necessitating these hysterectomies remain unknown. The purpose of this study was to determine which patients can continue conservative treatment for adenomyosis. METHODS: We selected women diagnosed with adenomyosis and provided with conservative treatment at the Kindai University Hospital and Osaka Red Cross Hospital in Osaka Japan from 2008 to 2017. Age at diagnosis, parity, uterine size, subtype of adenomyosis, type of conservative treatment, and timing of hysterectomy for cases with difficulty continuing conservative treatment were examined retrospectively. RESULTS: A total of 885 patients were diagnosed with adenomyosis, and 124 started conservative treatment. Conservative treatment was continued in 96 patients (77.4%) and hysterectomy was required in 28 patients (22.6%). The cumulative hysterectomy rate was 32.4%, and all women had hysterectomy within 63 months. In the classification tree, 82% (23/28) of women aged 46 years or younger were able to continue conservative treatment when parity was zero or one. In those with parity two and over, 95% (20/21) of those aged 39 years and older had hysterectomy. CONCLUSIONS: Patients who continue conservative treatment for approximately 5 years are more likely to have successful preservation of the uterus. Multiparity and higher age at diagnosis are factors that contribute to hysterectomy after conservative treatment. Parity and age at diagnosis may be stratifying factors in future clinical trials of hormone therapy.
format Online
Article
Text
id pubmed-8714452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87144522022-01-05 Characterization of patients that can continue conservative treatment for adenomyosis Miyagawa, Chiho Murakami, Kosuke Tobiume, Takako Nonogaki, Takafumi Matsumura, Noriomi BMC Womens Health Research BACKGROUND: Historically, hysterectomy has been the radical treatment for adenomyosis. Although, some patients may not want to have their uterus removed, patients often have to no choice but to request hysterectomy during conservative treatment. The factors necessitating these hysterectomies remain unknown. The purpose of this study was to determine which patients can continue conservative treatment for adenomyosis. METHODS: We selected women diagnosed with adenomyosis and provided with conservative treatment at the Kindai University Hospital and Osaka Red Cross Hospital in Osaka Japan from 2008 to 2017. Age at diagnosis, parity, uterine size, subtype of adenomyosis, type of conservative treatment, and timing of hysterectomy for cases with difficulty continuing conservative treatment were examined retrospectively. RESULTS: A total of 885 patients were diagnosed with adenomyosis, and 124 started conservative treatment. Conservative treatment was continued in 96 patients (77.4%) and hysterectomy was required in 28 patients (22.6%). The cumulative hysterectomy rate was 32.4%, and all women had hysterectomy within 63 months. In the classification tree, 82% (23/28) of women aged 46 years or younger were able to continue conservative treatment when parity was zero or one. In those with parity two and over, 95% (20/21) of those aged 39 years and older had hysterectomy. CONCLUSIONS: Patients who continue conservative treatment for approximately 5 years are more likely to have successful preservation of the uterus. Multiparity and higher age at diagnosis are factors that contribute to hysterectomy after conservative treatment. Parity and age at diagnosis may be stratifying factors in future clinical trials of hormone therapy. BioMed Central 2021-12-28 /pmc/articles/PMC8714452/ /pubmed/34961515 http://dx.doi.org/10.1186/s12905-021-01577-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Miyagawa, Chiho
Murakami, Kosuke
Tobiume, Takako
Nonogaki, Takafumi
Matsumura, Noriomi
Characterization of patients that can continue conservative treatment for adenomyosis
title Characterization of patients that can continue conservative treatment for adenomyosis
title_full Characterization of patients that can continue conservative treatment for adenomyosis
title_fullStr Characterization of patients that can continue conservative treatment for adenomyosis
title_full_unstemmed Characterization of patients that can continue conservative treatment for adenomyosis
title_short Characterization of patients that can continue conservative treatment for adenomyosis
title_sort characterization of patients that can continue conservative treatment for adenomyosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714452/
https://www.ncbi.nlm.nih.gov/pubmed/34961515
http://dx.doi.org/10.1186/s12905-021-01577-x
work_keys_str_mv AT miyagawachiho characterizationofpatientsthatcancontinueconservativetreatmentforadenomyosis
AT murakamikosuke characterizationofpatientsthatcancontinueconservativetreatmentforadenomyosis
AT tobiumetakako characterizationofpatientsthatcancontinueconservativetreatmentforadenomyosis
AT nonogakitakafumi characterizationofpatientsthatcancontinueconservativetreatmentforadenomyosis
AT matsumuranoriomi characterizationofpatientsthatcancontinueconservativetreatmentforadenomyosis